Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis

Am J Hematol. 2021 May 1;96(5):E146-E150. doi: 10.1002/ajh.26119. Epub 2021 Feb 19.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Cladribine / administration & dosage
  • Cladribine / pharmacology
  • Cladribine / therapeutic use*
  • Combined Modality Therapy
  • Disease Progression
  • Drug Evaluation
  • Female
  • Histiocytosis, Langerhans-Cell / diagnostic imaging
  • Histiocytosis, Langerhans-Cell / drug therapy*
  • Histiocytosis, Langerhans-Cell / physiopathology
  • Histiocytosis, Langerhans-Cell / therapy
  • Humans
  • Kaplan-Meier Estimate
  • MAP Kinase Signaling System / drug effects
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Mutation, Missense
  • Point Mutation
  • Positron Emission Tomography Computed Tomography
  • Progression-Free Survival
  • Proto-Oncogene Proteins B-raf / genetics
  • Pulmonary Diffusing Capacity / drug effects
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Cladribine
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf